FDA Grants Accelerated Approval to Rubraca for BRCA-positive Advanced Ovarian Cancer

FDA Grants Accelerated Approval to Rubraca for BRCA-positive Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology’s drug candidate Rubraca (rucaparib) to treat women with BRCA-positive advanced ovarian cancer, who have been treated with two or more chemotherapies. “Today’s approval is another example of the trend we are seeing in developing targeted agents to treat cancers caused by specific mutations in

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *